Interferon therapy for HCV-associated glomerulonephritis: Meta-analysis of controlled trials

International Journal of Artificial Organs

Volumn 30, Issue 3, 2007, Pages 212-219

  Fabrizi, Fabrizio ^a,b   Bruchfeld, A ^c   Mangano, S ^d   Dixit, V ^e   Messa, P ^a   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Sant'Anna Como Hospital   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glomerulonephritis (GN); Hepatitis C virus (HCV); Interferon (IFN); Meta analysis

Indexed keywords

ANTIBIOTICS; BODY FLUIDS; GLYCOPROTEINS; RANDOM PROCESSES; VIRUSES;

ANTIVIRALS; CLINICAL TRIAL; FOLLOW UP; GLOMERULONEPHRITIS; HEPATITIS C VIRUS; IMMUNOSUPPRESSIVE THERAPY; INTERFERON; INTERFERON THERAPY; META-ANALYSIS;

SENSITIVITY ANALYSIS;

ALPHA INTERFERON; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LYMPHOBLAST INTERFERON; PEGINTERFERON; RIBAVIRIN;

CHRONIC GLOMERULONEPHRITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEPATITIS C VIRUS; HUMAN; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; META ANALYSIS; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; RECURRENCE RISK; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34248398540     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000306     Document Type: Review

References (52)

1. Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, Davis C, Gretch DR. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46: 1255-63.
2. Jefferson JA, Johnson RJ. Treatment of hepatitis C-associated glomerular disease. Semin Nephrol 2000; 20: 286-92.
3. Garini G, Allegri L, Vaglio A, Buzio C. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Ital Med 2005; 20: 71-80.
4. Kasuno K, Ono T, Matsumori A, Nogaki F, Kusano H, Watanabe H, Yodoi J, Muso E. Hepatitis C virus associated tubulo-interstitial injury. Am J Kidney Dis 2003; 41: 767-75.
5. Hoch B, Jucknevicius I, Liapis H. Glomerular injury associated with hepatitis C infection: a correlation with blood and tissue HCV PCR. Semin Diag Pathol 2002; 19: 175-87.
6. Misiani R, Vicari O, Bellavita PM, Sonzogni A, Marin MG. Hepatitis C virus in renal tissue of patients with glomerulonephritis (letter). Nephron 1994; 68: 400.
7. Rodriguez-Inigo E, Casqueiro M, Bartolomè J, Barat A, Caramelo C, Ortiz A, Albalate M, Oliva H, Manzano ML, Carreno V. Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J Viral Hepat 2000; 7: 23-9.
8. Okada K, Takishita Y, Shimomura H, Tsuji T, Miyamura T, Kuhara T, Yasumoto K, Kagami S, Kuroda Y. Detection of hepatitis C core protein in the glomeruli of patients with membranous glomerulonephritis. Clin Nephrol 1996; 45: 71-76.
9. Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus infected-patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 1997; 25: 1237-44.
10. Sansonno D, Lauletta G, Montrone M, Grandaliano G, Schena FP, Dammacco F. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005; 140: 498-506.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
12. Yamabe H, Johnson RJ, Gretch DR, Osawa H, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y, Sato A, Onodera K. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25: 67-9.
13. Stehman-Breen C, Alpers CE, Couser WG, Willson R, Johnson RJ. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44: 141-47.
14. Morosetti M, Sciarra G, Meloni C, Palmieri G, Palombo G, Taccone Gallucci M, Casciani CU. Membranoproliferative glomerulonephritis and hepatitis C: effects of interferon-alpha therapy on clinical outcome and histologic pattern. Nephrol Dial Transplant 1996; 11: 532-4.
15. Gilli P, Stabellini N, Storari A, Gualandi G, Guerra G, Ghinelli F. Effect of human leukocyte alpha interferon on cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplant 1996; 11: 526-8.
16. Sarac E, Bastacky S, Johnson JP. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997; 30: 113-5.
17. Laganovic M, Jelakovic B, Kuzmanic D, Scukanec-Spoliar M, Roncevic T, Cuzic S, Ostojic R. Complete remission of cyoglobulinemic glomerulonephritis (HCV-positive) after high dose interferon therapy. Wien Klin Wochenschr 2000; 112: 596-600.
18. Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001; 38: E1-E9.
19. Reed MJ, Alexander GJM, Thiru S, Smith KGC. Hepatitis C-associated glomerulonephritis- a novel therapeutic approach. Nephrol Dial Transplant 2001; 16: 869-71.
20. Willson RA. The benefit of long-term interferon alfa therapy for symptomatic mixed cryoglobulinemia (cutaneous vasculitis/ membranoproliferative glomerulonephritis) associated with chronic hepatitis C infection. J Clin Gastroenterol 2001; 33: 137-140.
21. Loustaud-Ratti V, Liozon E, Karaslan H, Alain S, Paraf F, Le Maur Y, Denis F, Vidal E. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 2002; 113: 516-9.
22. Perez Calvo J, Lasierra P, Moros M, Inigo P. Role of ribavirin in membranoproliferative glomerulonephritis associated with hepatitis C virus infection refractory to alpha-IFN. Nephron 2002; 92: 459-62.
23. Guarnieri A, Marazzi F, Giorgi MP, Canepari G, Pino C, Moggia E, Manca A, Ghezzi PM. Steroids, interferon-alpha, and ribavirin treatment of cryoglobulinemic glomerulonephritis concurrent with HCV infection. G Ital Nefrol 2002; 19: 78-81.
24. Lopes EPA, Valente LM, Silva AEB, Mastroianni Kirsztajn G, Cruz CN, Ferraz MLG. Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus. Braz J Infect Dis 2003; 7: 1-7.
25. Hu SL, Jaber BL. Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy. Clin Nephrol 2005; 63: 41-5.
26. Rossi P, Bertani T, Baio P, Caldara R, Luliri P, Tengattini F, Bellavita PM, Mazzucco G, Misiani R. Hepatitis C virus related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-41.
27. Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Malik G, Khalil M. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999; 33: 1142-6.
28. Sabri AA, Sobh MA, Sheasha HA, Kudesia G, Wild G, Fox S, Wagner BE, Irving WL, Grabowska A, El-Nahas AM. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002; 17: 1924-30.
29. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-80.
30. Poynard T, Conn HO. The retrieval of randomised clinical trials in liver diseases from the medical literature: A comparison of Medlars and manual methods. Control Clin Trials 1985; 6: 271-9.
31. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. Br J Med 2003; 327: 557-60.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
33. Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, Hart J, Willson R. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46: 1700-4.
34. Misiani R, Bellavita PM, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, Tanzi E, Zanetti A. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.
35. Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T, Oyama Y, Nakamoto Y. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med 1996; 35: 529-33.
36. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, Baracetti S, Nascimben F, Zorat F, Pozzato G, Faccini L, Campanacci L. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000; 32: 708-15.
37. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine 2002; 81: 398-409.
38. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-23.
39. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Giachino O, Mazzucco G, Sena LM. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-61.
40. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, Marchi GD, Fabris M, Ferraccioli G, Vita SD. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006; 45: 842-6.
41. Rosenstock JL, Stern L, Sherman WH, Appel GB, Radhakrishnan J. Fludarabine treatment of cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2002; 40: 644-8.
42. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, de Marchi G, Michelutti A, Baccarano M, Fanin R, Ferraccioli GF. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
43. Sansonno D, De Re V, Lauletta GF, Tucci AF, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101: 3818-26.
44. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeit O, Arlt AC, Solbach W, Gross WL. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003; 62: 1230-33.
45. Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haem 2006; 28: 211-4.
46. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006; 17: 1168-74.
47. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006; 69: 436-9.
48. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81.
49. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. Br Med J 2001; 323: 42-6.
50. Tarantino A, Campise MR, Banfi G, Confalonieri R, Bucci A, Montoli A, Colasanti G, Damilano I, D'Amico G, Minetti L, Ponticelli C. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-23.
51. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
52. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996; 156: 661-6.